Moshe SL, Perucca E, Ryvlin P et al (2015) Epilepsy: new advances. Lancet 385:884–898

Article  PubMed  Google Scholar 

Pharma U Vimpat® (lacaosmide): EMA summary of product characteristics. https://www.emaeuropaeu/en/documents/product-information/vimpat-epar-product-information_enpdf

US Food and Drug Administration (2013) Vimpat (lacosamide) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022253s024,022254s018,022255s010lbl.pdf; [accessed1.2.17]

Vossler DG, Knake S, O’Brien TJ et al (2020) Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double- blind, randomised, placebo- controlled trial. J Neurol Neurosurg Psychiatry 91:1067–1075

Article  PubMed  Google Scholar 

Arabi M, Alsaadi T, Nasreddine W et al (2018) Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region. Epilepsy Behav 84:118–121

Article  PubMed  Google Scholar 

Biton V, Gil-Nagel A, Isojärvi J et al (2015) Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 52:119–127

Article  PubMed  Google Scholar 

Zadeh WW, Escartin A, Byrnes W et al (2015) Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial. Seizure 31:72–79

Article  PubMed  Google Scholar 

Zhao T, Li HJ, Ma L et al (2021) Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur, China. Epilepsy Behav 117:107814

Article  PubMed  Google Scholar 

Zhao T, Li HJ, Zhang HL et al (2023) Twelve-month efficacy of lacosamide monotherapy at maximal dose and tolerability for epilepsy treatment in pediatric patients: Real-world clinical experience. Pediatr Neurol 142:23–30

Article  PubMed  Google Scholar 

Zhao T, Yu LH, Zhang HL et al (2023) Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: A real-world study. BMC Pediatr 23(1):249

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao T, Li HJ, Zhang HL et al (2023) Therapeutic drug monitoring of lacosamide in Chinese pediatric patients with epilepsy: efficacy and factors influencing the plasma concentration. Eur J Drug Metab Pharmacokinet 48(1):41–49

Article  PubMed  CAS  Google Scholar 

Contin M, Albani F, Riva R et al (2013) Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 35(6):849–852

Article  PubMed  CAS  Google Scholar 

Yamamoto Y, Terada K, Araki Y et al (2020) Therapeutic monitoring of lacosamide in japanese patients with epilepsy: clinical response, tolerability, and optimal therapeutic range. Ther Drug Monit 42(5):754–759

Article  PubMed  CAS  Google Scholar 

Cawello W, Stockis A, Andreas J et al (2014) Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci 1329:18–32

Article  PubMed  CAS  Google Scholar 

Cawello W, Boekens H, Bonn R (2012) Absorption, disposition, metabolic fate and elimination of the anti- epileptic drug lacosamide in humans: mass balance following intravenous and oral administration. Eur J Drug Metab Pharmacokinet 37:241–248

Article  PubMed  CAS  Google Scholar 

Svendsen T, Brodtkorb E, Baftiu A et al (2017) Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability. Neurochem Res 42(7):2077–2083

Article  PubMed  CAS  Google Scholar 

May TW, Helmer R, Bien CG et al (2018) Influence of dose and antiepileptic comedication on lacosamide serum concentrations in patients with epilepsy of different ages. Ther Drug Monit 40(5):620–627

Article  PubMed  CAS  Google Scholar 

Scheffer IE, Berkovic S, Capovilla G et al (2017) ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58:512–521

Article  PubMed  PubMed Central  Google Scholar 

Zhao T, Li HJ, Wang TT et al (2020) Development and validation of an innovative UPLC method to quantify lacosamide, oxcarbazepine and lamotrigine in the serum of children with epilepsy in China. Biomed Chromatogr 09:e5022

Google Scholar 

Guidelines I (1989) Guidelines for clinical evaluation of antiepileptic drugs. Commission on Antiepileptic Drugs of the International League Against Epilepsy. Epilepsia 30:400–408

Article  Google Scholar 

Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97–98

Article  PubMed  CAS  Google Scholar 

Svendsen T, Brodtkorb E, Baftiu A et al (2017) Therapeutic drug monitoring of lacosamide in Norway: focus on pharmacokinetic variability, efficacy and tolerability. Neurochem Res 42:2077–2083

Article  PubMed  CAS  Google Scholar 

Cawello W (2015) Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet 54:901–914

Article  PubMed  CAS  Google Scholar 

Markoula S, Teotonio R, Ratnaraj N et al (2014) Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit 36:494–498

Article  PubMed  CAS  Google Scholar 

Burns ML, Nikanorova M, Baftiu A et al (2019) Pharmacokinetic variability and clinical use of lacosamide in children and adolescents in Denmark and Norway. Ther Drug Monit 41(3):340–347

Article  Google Scholar 

Schaefer C, Cawello W, Waitzinger J et al (2015) Effect of age and sex on lacosamide pharmacokinetics in healthy adult subjects and adults with focal epilepsy. Clin Drug Investig 35(4):255–265

Article  PubMed  CAS  Google Scholar 

Schultz L, Mahmoud SH (2020) Is therapeutic drug monitoring of lacosamide needed in patients with seizures and epilepsy? Eur J Drug Metab Pharmacokinet 45(3):315–349

Article  PubMed  CAS  Google Scholar 

Winkler J, Schoemaker R, Stockis A (2019) Population pharmacokinetics of adjunctive lacosamide in pediatric patients with epilepsy. J Clin Pharmacol 59(4):541–547

Article  PubMed  CAS  Google Scholar 

Hillenbrand B, Wisniewski I, Jürges U, Steinhoff BJ (2011) Add- on lacosamide: a retrospective study on the relationship between serum concentration, dosage, and adverse events. Epilepsy Behav 22:548–551

Article  PubMed  Google Scholar 

Ahn SJ, Oh J, Kim DY et al (2022) Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. Epilepsia 63(11):2958–2969

Article  PubMed  CAS  Google Scholar 

Hyland R, Jones BC, Smith DA (2003) Identifica- tion of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540–547

Article  PubMed  CAS  Google Scholar 

Theuretzbacher U, Ihle F, Derendorf H (2006) Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649–663

Article  PubMed  CAS  Google Scholar 

Chen L, Qin S, Xie J et al (2008) Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 9(6):691–702

Article  PubMed  CAS  Google Scholar 

Petrović J, Pešić V, Lauschke VM (2020) Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet 28:88–94

Article  PubMed  Google Scholar